covid19vaccine

Misinformation around covid-19 and vaccines is rife and as the data available increases, so do often misleading and even wild claims. This week More or Less examines multiple viral claims that the Covid 19 mRNA vaccines increase the risk of miscarriage. To explain where these incorrect figures come from and what the science actually tells us, we are joined by Dr Viki Male, senior lecturer in reproductive immunology at Imperial College London. Presenter: Charlotte McDonald, Producers: Octavia Woodward and Jon Bithrey Editor: Richard Vadon Sound Engineer: John Scott Production Co-ordinator: Helena Warwick-Cross

(Photo by Matthew Horwood/Getty Images)

In this episode Nicolai Tangen talks to Stephane Bancel, CEO of Moderna. They discuss vaccine rollouts, China’s zero-Covid policy, ethical dilemmas in the pharma industry and much more.

The production team on this episode were Plan B’s Tor-Erik Humlen and Olav Haraldsen Roen. Background research were done by Sigurd Brekke and Bård Ove Molberg with additional input from our portfolio manager Mark Dainty.

Hosted on Acast. See acast.com/privacy for more information.

Joe Biden announces vaccines for all by May 1st and Donald Trump wants credit, Tan Suit journalism returns as some political reporters work hard to generate Biden controversies, Andrew Cuomo faces more calls to resign, and progressives are concerned about some of the President’s foreign policy decisions during his first fifty days in office.

For a closed-captioned version of this episode, please visit crooked.com/podsaveamerica. 

For a transcript of this episode, please email transcripts@crooked.com and include which podcast you would like.

North Dakota and New Orleans have been hit particularly hard by the coronavirus.

On today’s episode, we speak to health care workers in both places as they become some of the first to receive and administer the vaccine, and tap into the mood of hope and excitement tempered by a bleak fact: The battle against Covid-19 is not yet over.

Guest: Jack Healy, a national correspondent for The New York Times.

For an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. You can read the latest edition here.

Background reading:

• Monday’s vaccinations, the first in a staggeringly complicated national campaign, were a moment infused with hope and pain for hundreds of America’s health care workers.
• Some of the very medical centers that have endured the worst of the coronavirus found the gloom that has long filled their corridors replaced by elation. The vaccine campaign, however, began on the same day that America surpassed 300,000 deaths from Covid-19.

For more information on today’s episode, visit nytimes.com/thedaily

In Britain, news that the country had become the first to start administering a fully tested coronavirus vaccine was met with hope, excitement — and some trepidation.

Amid the optimism that normal life might soon resume, there is also concern. Has the vaccine been developed too fast? Is it safe? On today’s episode, we examine how Britons feel about the prospect of receiving a shot and attend a vaccination clinic in Wales.

Guest: Megan Specia, a story editor based in London for the New York Times.

For an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter. You can read the latest edition here.

Background reading:

• For the first recipients of the vaccine, among them older Britons and hundreds of doctors and nurses who pulled the National Health Service through the pandemic, the shots offered a glimpse at a return to normalcy.
• Dr. Chris Hingston was one of the first health care workers in Britain to receive the vaccine. He was clearly aware that the simple act had a greater purpose: protecting not only himself, but hopefully his family, colleagues and patients from a potentially life-threatening virus.

For more information on today’s episode, visit nytimes.com/thedaily

For Americans, months of collective isolation and fear could soon be winding down. A coronavirus vaccine may be just weeks away.

According to Dr. Moncef Slaoui, head of Operation Warp Speed, the federal effort to accelerate vaccine development, the first Americans could receive the vaccine in mid-December.

With the vaccine within reach, we turn to more logistical questions: Who will receive the shots first? Who will distribute them? And what could go wrong?

Guest: Katie Thomas, who covers the drug industry for The New York Times.

We want to hear from you. Fill out our survey about The Daily and other shows at: nytimes.com/thedailysurvey

For more information on today’s episode, visit nytimes.com/thedaily

Background reading:

• Promising clinical trials have buoyed hope that the end of the pandemic is in sight. But even if the vaccines are authorized, only a sliver of the American public will be able to get one by the end of the year.
• In mid-December, 6.4 million doses of Pfizer’s vaccine are expected to be shipped across the United States in an initial push.

It’s a dark time in the struggle with the coronavirus, particularly in the United States, where infections and hospitalizations have surged.

But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine is 90 percent effective in preventing Covid-19.

With the virus raging, how strong is this new ray of hope?

Guest: Carl Zimmer, a science writer and author of the “Matter” column for The New York Times.

Background reading:

• Pfizer has announced positive early results from its coronavirus vaccine trial, cementing the lead in a frenzied global race that has unfolded at record-breaking speed.
• Meet the couple behind the German company, BioNTech, that partnered with Pfizer to develop the vaccine.

We want to hear from you. Fill out our survey about this show and others at nytimes.com/thedailysurvey.

We explore the science, scalability, and (of course) economics surrounding the global vaccine race. Guests include the chief medical officer of the first U.S. firm to go to Phase 3 trials with a vaccine candidate; a former F.D.A. commissioner who’s been warning of a pandemic for years; and an economist who thinks Covid-19 may finally change how diseases are cured.

Operation Warp Speed has in some ways lived up to its name: The U.S. government has awarded almost $11 billion to seven different companies to develop vaccines, three of which — Moderna, AstraZeneca and Pfizer — are in late-stage trials.

Things are going according to the most aggressive schedule.

However, accelerating the development process has increased the likelihood of cronyism and undue political influence.

Today, we ask whether the White House’s defiance of the timelines that have long governed the development of vaccines is working.

Guest: Katie Thomas, a reporter at The New York Times who covers the health care sector, with a focus on the drug industry.

For more information on today’s episode, visit nytimes.com/thedaily

Background reading:

• There is a lot of optimism surrounding the coronavirus vaccine and its potential to usher in a return to normality in the near future — but doctors warn that those expectations ought to be tempered.
• With thousands dying, economic tumult and a looming election, the U.S. government is eager to start vaccinating as soon as possible. Experts worry that the Trump administration will push the Food and Drug Administration to overlook insufficient data.
• The vaccine effort has spelled big profits for corporate insiders.

Trevor likens President Trump to Joe Exotic from "Tiger King," Jaboukie Young-White chats with Dr. Peter Hotez, and California Governor Gavin Newsom discusses the coronavirus.

See omnystudio.com/listener for privacy information.